Intravenous (IV) Ibuprofen Market Report by Product Dose (100 Mg Dose, 200 Mg Dose, 400 Mg Dose, 800 Mg Dose), Indication (Pain/Inflammatory, Fever), Age Group (Pediatrics, Adults), and Region 2025-2033

Intravenous (IV) Ibuprofen Market Report by Product Dose (100 Mg Dose, 200 Mg Dose, 400 Mg Dose, 800 Mg Dose), Indication (Pain/Inflammatory, Fever), Age Group (Pediatrics, Adults), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A6440

Market Overview:

The global intravenous (IV) ibuprofen market size reached USD 7.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.45% during 2025-2033.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 7.3 Billion
Market Forecast in 2033
USD 13.2 Billion
Market Growth Rate (2025-2033) 6.45%


Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.

Intravenous (IV) Ibuprofen Market Trends:

The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor. Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth. Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofen market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product dose, indication and age group.

Breakup by Product Dose:

  • 100 Mg Dose
  • 200 Mg Dose
  • 400 Mg Dose
  • 800 Mg Dose
     

Breakup by Indication:

  • Pain/Inflammatory
  • Fever
     

Breakup by Age Group:

  • Pediatrics
  • Adults
     

Breakup by Region:

Intravenous (IV) Ibuprofen Market By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Product Dose, Indication, Age Group, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global Intravenous (IV) ibuprofen market was valued at USD 7.3 Billion in 2024.

We expect the global Intravenous (IV) ibuprofen market to exhibit a CAGR of 6.45% during 2025-2033.

The rising prevalence of arthritis, cancer, rheumatoid disorders, etc., along with the growing adoption of IV ibuprofen, as it assists in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries, is primarily driving the global Intravenous (IV) ibuprofen market.

The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for Intravenous (IV) ibuprofen to relieve several symptoms of coronavirus infection, such as inflammation, pain, fever, etc.

Based on the indication, the global Intravenous (IV) ibuprofen market has been segregated into pain/inflammatory and fever, where pain/inflammatory currently exhibits a clear dominance in the market.

Based on the age group, the global Intravenous (IV) ibuprofen market can be bifurcated into pediatrics and adults. Currently, adults hold the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global Intravenous (IV) ibuprofen market include Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA, and Xgen Pharmaceuticals Djb Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Intravenous (IV) Ibuprofen Market Report by Product Dose (100 Mg Dose, 200 Mg Dose, 400 Mg Dose, 800 Mg Dose), Indication (Pain/Inflammatory, Fever), Age Group (Pediatrics, Adults), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials